A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment

Jeffrey A. Cohen, Michelle H. Cameron, Myla D. Goldman, Andrew D. Goodman, Aaron E. Miller, Anne Rollins, Lily Llorens, Rajiv Patni, Robert Elfont, Reed Johnson

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment'. Together they form a unique fingerprint.

Medicine & Life Sciences